2021-01-29T08:38:16-06:00 2020-06-30 410746749 CLIFTONLARSONALLEN LLP 801 FELIX STREET ST JOSEPH MO 64501 990 2019-07-01 431266906 PKD FOUNDATION PKDF 8169312600 1001 E 101ST TER NO 220 KANSAS CITY MO 64131 ANDY BETTS PRESIDENT AND CEO 8169312600 2021-01-27 1 HAROLD RAY P01248589 8162328441 2021-01-27 2019 2022-09-23 18:48:47Z ANDY BETTS 1001 E 101ST TER NO 220 KANSAS CITY MO 64131 31731951 0 X WWW.PKDCURE.ORG X 1982 MO PROMOTE PROGRAMS OF RESEARCH AND EDUCATION TO DISCOVER TREATMENTS AND A CURE FOR PKD. 16 15 54 3509 0 0 6507595 15841230 0 0 217531 281624 34477 1595 6759603 16124449 2960317 1565964 0 0 3127659 3094016 137813 324724 1215677 1944168 2257239 8169957 7241943 -1410354 8882506 10606466 20909832 1852410 3109449 8754056 17800383 X PROMOTE PROGRAMS OF RESEARCH, ADVOCACY, EDUCATION, SUPPORT AND AWARENESS IN ORDER TO DISCOVER TREATMENTS AND A CURE FOR POLYCYSTIC KIDNEY DISEASE AND IMPROVE THE LIVES OF ALL IT AFFECTS. 0 0 2801908 1565964 0 SINCE ITS FOUNDING IN 1982, THE PKD FOUNDATION HAS INVESTED MORE THAN $50 MILLION IN RESEARCH, CLINICAL AND SCIENTIFIC GRANTS, AWARDS, FELLOWSHIPS AND SCIENTIFIC MEETINGS, MAKING IT THE LARGEST PRIVATE FUNDER OF POLYCYSTIC KIDNEY DISEASE (PKD) RESEARCH. THE FOUNDATION'S FINANCIAL COMMITMENT OVER THE YEARS HAS SEEN RESULTS ON A LOCAL, NATIONAL AND EVEN GLOBAL LEVEL, INCLUDING INITIATING FUNDING FOR YOUNG INVESTIGATORS FROM AROUND THE WORLD; SUPPORTING INNOVATIVE RESEARCH IDEAS; AND PROVIDING SEED FUNDING TO RESEARCH TO ALLOW RESEARCHERS WORLD-WIDE TO APPLY FOR LARGER NATIONAL INSTITUTES OF HEALTH (NIH) GRANTS. THE FOUNDATION'S FISCAL YEAR INVESTMENTS IN RESEARCH IS OUTLINED BELOW.RESEARCH GRANTS: INVESTED $1,110,500 ON GRANT FUNDING TO 19 PKD PROJECTS THAT FOCUS ON RISK FACTORS FOR PKD MANIFESTATIONS, BETTER UNDERSTANDING OF CELLULAR MECHANISMS THAT ACCELERATE PROGRESSION AND IDENTIFYING TARGETS FOR PKD. FELLOWSHIPS: PROVIDED $180,000 IN FELLOWSHIP FUNDING TO 3 SUPPORT TRAINEES IN OBTAINING RESEARCH EXPERIENCE AS THEY INITIATE CAREERS IN PKD.CORE GRANTS: INVESTED $66,000 TO SUPPORT CORE RESEARCH GRANTS SERVICES AND RESOURCES FOR PKD SCIENTISTS IN A PROMINENT GENETIC LAB SO THAT FOUNDATION DOLLARS CAN BE LEVERAGED ACROSS THE PKD RESEARCH COMMUNITY.ADPKD REGISTRY: LED THE DEVELOPMENT AND IMPLEMENTATION OF THE NATION'S FIRST ADPKD PATIENT REGISTRY TO COLLECT VALUABLE DATA ABOUT THE PKD EXPERIENCE DIRECTLY FROM PATIENTS AND SUPPORT THE RECRUITMENT OF PARTICIPANTS FOR CLINICAL STUDIES. POLYCYSTIC KIDNEY DISEASE OUTCOMES CONSORTIUM: INVESTED $100,000 IN COLLABORATION BETWEEN THE PKD FOUNDATION, CRITICAL PATH INSTITUTE, REPRESENTATIVES OF THE PHARMACEUTICAL INDUSTRY, PKD CLINICIANS AND THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO FACILITATE CLINICAL TRIAL DEVELOPMENT FOR PKD THERAPIES. 1362676 0 3372 AWARENESS AND ADVOCACY:THE FOUNDATION USES MARKETING TO INCREASE DISEASE AWARENESS, PROMOTE THE FOUNDATION'S SERVICES, AND INSPIRE THE PUBLIC TO SUPPORT THE FOUNDATION'S MISSION. MARKETING MATERIALS INCLUDE PKD LIFE MAGAZINE, A MONTHLY EMAIL NEWSLETTER, SOCIAL MEDIA, THE PKD BLOG AND PKDCURE.ORG.THE FOUNDATION HAS AN ACTIVE SOCIAL MEDIA COMMUNITY, REACHING MORE THAN 34,000 FACEBOOK FANS, 7,000 TWITTER FOLLOWERS, 5,000 INSTAGRAM FOLLOWERS, AND 1,500 LINKEDIN FOLLOWERS. PKDCURE.ORG RECEIVED 998,612 UNIQUE VISITS AND PKDCONNECTION.ORG RECEIVED 268,609 VISITS.THE FOUNDATION ADVOCATES FOR PKD PATIENTS IN POLICYMAKING, DRUG DEVELOPMENT, AND REGULATORY DECISION-MAKING AT THE CONGRESSIONAL AND FEDERAL LEVEL. THE PKD ADVOCACY ACTION CENTER (PKDCURE.ORG/ADVOCACY) SENT ADVOCACY ALERTS TO 13,000 PKD ADVOCATORS ABOUT LEGISLATIVE AND PUBLIC POLICY ISSUES IMPACTING PKD PATIENTS AND FAMILIES. THE FOUNDATION JOINS WITH OTHER KIDNEY DISEASE-RELATED ORGANIZATIONS IN EVENTS THAT ALLOW ADVOCATES TO MEET WITH MEMBERS OF CONGRESS TO RAISE AWARENESS OF PKD AND DISCUSS LEGISLATIVE PRIORITIES. 985963 0 0 EDUCATION AND SUPPORT:THE PKD FOUNDATION SUPPORTS THE PKD COMMUNITY THROUGH MORE THAN 55 VOLUNTEER-LED CHAPTERS ACROSS THE UNITED STATES. CHAPTERS PROVIDE MEANINGFUL OPPORTUNITIES FOR THE LOCAL COMMUNITY TO GATHER TOGETHER AND LEARN FROM EXPERTS OR IN SUPPORT OF EACH OTHER. PKD FOUNDATION VOLUNTEERS BRING TO LIFE THE MISSION OF THE ORGANIZATION BY ENSURING THAT NO ONE FACES THIS DISEASE ALONE. EDUCATION MEETINGS PROVIDE VALUABLE INFORMATION ON TOPICS RANGING FROM CURRENT RESEARCH TO DISEASE MANAGEMENT, WHILE SUPPORT ACTIVITIES RANGE FROM LENDING A LISTENING EAR TO ORGANIZED SOCIAL GATHERINGS. THE FOUNDATION HAS MORE THAN 1871 ACTIVE VOLUNTEERS.CHAPTER COMMUNITIES RAISE FUNDS FOR THE FOUNDATION THROUGH EVENTS WHICH ALSO INCREASE AWARENESS OF PKD AND CONNECT LOCAL PATIENTS AND FAMILIES TO EACH OTHER. SIXTY-FIVE LOCAL FUNDRAISING AND THIRD- PARTY EVENTS WERE HELD THIS YEAR THAT RAISED $449,731. CHAPTER COMMUNITIES ALSO RAISE AWARENESS AND MONEY THROUGH THE WALK FOR PKD, THE FOUNDATION'S SIGNATURE FUNDRAISING AND PUBLIC AWARENESS EVENT. THE WALK TOOK PLACE IN 54 CITIES ACROSS THE NATION EACH YEAR AND HAS RAISED NEARLY $33 MILLION SINCE 2000.ON A NATIONAL LEVEL, THE PKD FOUNDATION EMPOWERS PKD PATIENTS AND CAREGIVERS TO MANAGE PKD WHILE MAINTAINING A HIGH QUALITY OF LIFE. THE FOUNDATION PROVIDES RESOURCES ACROSS THE CONTINUUM OF DISEASE PROGRESSION FOR PATIENTS, CAREGIVERS, PARENTS, ETC. RESOURCES INCLUDE WEBINARS, ENDURING WEBCASTS, VIDEOS, A COMPREHENSIVE WEBSITE (PKDCURE.ORG/LEARN), HANDBOOKS AND OTHER PRINT MATERIALS. THE ADPKD PATIENT HANDBOOK AND THE ARPKD HANDBOOK ARE VALUABLE RESOURCES FOR PATIENTS AND FAMILIES LIVING WITH PKD. 267 HANDBOOKS WERE MAILED TO CONSTITUENTS AND 317 HANDBOOKS WERE DOWNLOADED. 5150547 1 1 0 1 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 1 1 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 11 0 54 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 X 16 15 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CO CT FL GA HI IL KS KY MA MD ME MI MN MS NC ND NH NJ NM NV NY OH OK OR PA RI SC TN UT VA WA WI WV X X X STEPHANIE BRENDEL 8169312600 1001 E 101ST TER NO 220 KANSAS CITY MO 64131 X BRAZELL BILL DIRECTOR 1.00 X 0 0 0 BROWN ASHLEY DIRECTOR 1.00 X 0 0 0 DELL KATHERINE DIRECTOR 1.00 X 0 0 0 HABERMANN GEORGINA DIRECTOR 1.00 X 0 0 0 KARL MICHELE DIRECTOR 1.00 X 0 0 0 KRINGSTEIN ANDREA DIRECTOR 1.00 X 0 0 0 MANGLANI NAVIN DIRECTOR 1.00 X 0 0 0 MRUG MICHAL DIRECTOR 1.00 X 0 0 0 RAMSEYER CRAIG DIRECTOR 1.00 X 0 0 0 TOWEY FRAN JR DIRECTOR 1.00 X 0 0 0 WAXMAN JERRY DIRECTOR 1.00 X 0 0 0 WESS CHRIS DIRECTOR 1.00 X 0 0 0 HUTCHINSON PAULA SECRETARY 1.00 X X 0 0 0 ROTH ROB TREASURER 1.00 X X 0 0 0 KLEBER KLEE VICE-CHAIR 2.00 X X 0 0 0 BENSON DR BEVERLY CHAIR 2.00 X X 0 0 0 BETTS ANDREW PRESIDENT AND CEO 40.00 X 268422 0 54457 HANOVA AMANDA CHIEF OPERATING OFFICER 40.00 X 156550 0 36582 SULLENS STEPHANIE CHIEF ADVANCEMENT OFFICER 40.00 X 153403 0 23849 BARON DAVID CHIEF RESEARCH OFFICER 40.00 X 148036 0 24367 DEREMER SUSAN DIRECTOR OF LEADERSHIP GIFTS 40.00 X 103020 0 20091 DENNY ALEXIS DIRECTOR OF GOVERNMENT AFFAIRS 40.00 X 103020 0 20091 932451 0 179437 6 0 1 0 MANIFEST LLC 228 E 45TH ST 7TH FLOOR NEW YORK NY 10017 PKDLIFE MAGAZINE PRODUCTION AND DELIVERY 324892 NEWPORT ONE 21 RAILRODA AVE DUXBURY MA 02332 DIGITAL AND DIRECT MAIL STRATEGY AND SOL 178952 IQVIA TECHNOLOGY SERVICES 210 PENTONVILLE RD LONDON UK N1 OYJ PATIENT REGISTRY AND CONSULTING FEES 114089 3 15841230 10170764 15841230 335777 335777 15551572 15605725 -54153 -54153 -54153 3372 1777 1595 1595 16124449 1595 0 281624 1355964 1355964 50000 50000 160000 160000 691328 437442 139998 113888 1718913 1090185 380527 248201 134947 89124 27921 17902 358806 228056 78341 52409 190022 120714 41014 28294 54613 37355 8335 8923 30210 19403 5982 4825 60000 60000 324724 324724 40657 40657 622878 535028 19721 68129 96005 79018 510 16477 141819 110318 15990 15511 51042 37461 13581 243211 165868 42810 34533 23681 23681 636435 418629 209 217597 186076 103664 48297 34115 19439 12485 3849 3105 DUES, FEES, MEMBERSHIPS 51173 16152 21558 13463 7241943 5150547 875719 1215677 X 208477 83774 0 124703 560278 837660 1336795 2329780 2888585 1975570 26148 53985 12805 246080 1110478 428139 740117 682339 5024730 14768885 17008 15533 10606466 20909832 852410 870271 400000 1000000 1441378 397800 1852410 3109449 X 4517567 4630854 4236489 13169529 8754056 17800383 10606466 20909832 X 8882506 154288 9533 X X 0 1 X 1 0 X 5881314 5709118 12652147 6507595 15841230 46591404 5881314 5709118 12652147 6507595 15841230 46591404 10129140 36462264 31733 73444 100878 145688 335777 687520 30462 39617 130100 35413 235592 47514516 26028 0.76740 0.91580 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2015 AMOUNT: $ 162. 2016 AMOUNT: $ 737. 2017 AMOUNT: $ 130,100. 2018 AMOUNT: $ 35,413. GROSS REVENUE FROM FUNDRAISING EVENTS - 2015 AMOUNT: $ 30,300. 2016 AMOUNT: $ 38,880. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 60000 60000 7181943 7241943 512097 128024 0 0 456460 536097 558498 512097 2063152 3094728 58865 60000 55000 60000 233865 114115 134024 139625 128024 515788 773682 4597077 9642300 399614 40657 14598334 4079744 409814 276814 148064 21231 4597077 2960433 1021831 222220 108000 16741 4079744 2773007 310566 108000 15140 2960433 2700000 77487 4480 2773007 0.28980 0.06850 0.64170 0 0 69356 12651 56705 1041122 415488 625634 682339 X 16498543 154288 258686 1777 414751 16083792 40657 40657 16124449 7452216 258686 -7756 250930 7201286 40657 40657 7241943 PART V, LINE 4: THE PURPOSE OF THE RESEARCH OPPORTUNITY FUND AND NAMED ENDOWMENTS (COLLECTIVELY REFERRED TO AS "ENDOWMENTS") IS TO PROVIDE FOR GROWTH-ORIENTED LONG-TERM INVESTMENT OF FUNDS THAT ARE NOT NEEDED TO MEET THE DAY-TO-DAY FINANCIAL OBLIGATIONS OF THE FOUNDATION. PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM INCOME TAXES UNDER SECTION 501(C)(3) OF THE U.S. INTERNAL REVENUE CODE. THE FOUNDATION DOES NOT OPERATE AS A PRIVATE FOUNDATION. ALTHOUGH IT IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES ON ITS PRINCIPAL OPERATIONS, THE FOUNDATION IS SUBJECT TO FEDERAL INCOME TAXES ON THE NET INCOME FROM ANY OPERATIONS IDENTIFIED BY THE INTERNAL REVENUE SERVICE TO GENERATE UNRELATED BUSINESS INCOME. NO SUCH UNRELATED BUSINESS INCOME TAX WAS INCURRED DURING 2020 OR 2019. THE FOUNDATION FOLLOWS THE STANDARDS FOR EVALUATING UNCERTAIN TAX POSITIONS AND HAS DETERMINED NO LIABILITY SHOULD BE RECORDED FOR UNCERTAIN TAX POSITIONS. PART XI, LINE 2D - OTHER ADJUSTMENTS: COST OF GOODS SOLD FOR MERCHANDISE SALES 1,777. PART XII, LINE 2D - OTHER ADJUSTMENTS: COST OF GOODS SOLD FOR MERCHANDISE SALES 1,777. RETURN OF PRIOR YEAR GRANT -9,533. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION N/A 80000 EAST ASIA & THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION N/A 80000 0 0 0 0 0 0 160000 0 160000 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM KETO-ADPKD - A PILOT TRIAL OF KETOGENIC DIETARY INTERVENTIONS IN ADPKD 80000 ACH TRANSFER BOOK EAST ASIA & THE PACIFIC INVESTIGATING A NEW REGULATOR OF CYST DEVELOPMENT IN PKD 80000 ACH TRANSFER BOOK 2 0 0 0 0 0 0 0 PART I, LINE 2: ALL GRANTEES ARE REQUIRED TO SUBMIT AN ANNUAL RESEARCH PROGRESS REPORT AND AN ANNUAL INSTITUTIONAL FINANCIAL STATUS REPORT. MOST GRANTEES ARE ALSO REQUIRED TO SUBMIT INTERIM QUARTERLY PROGRESS REPORTS. PART I, LINE 3: EXPENDITURES ARE REPORTED AT THE AMOUNT OF THE GRANT AWARDED AND ARE ACCOUNTED FOR USING THE SAME METHOD IN THE ORGANIZATION'S FINANCIAL STATEMENTS. PART III ACCOUNTING METHOD: X X X X X X 1 NEWPORT ONE 21 RAILROAD AVE DUXBURY MA 02332 MANAGED DIRECT MAIL EFFORTS 0 431783 247640 184143 431783 247640 184143 AK AL AR AZ CA CO CT FL GA HI IL KS KY MA MD ME MI MN MS NC ND NH NJ NM NV NY OH OK OR PA RI SC TN UT VA WA WI WV SCHEDULE G, PART I, LINE 2B, COLUMN (V) PAID PROFESSIONAL FUNDRAISER TO CREATE, PRINT AND SEND DIRECT MAIL CONTRIBUTION SOLICITATIONS. PAYMENTS WERE MADE BY CHECK. 1 UNIVERSITY OF DENVER PO BOX 910439 DENVER CO 80921 846000555 501(C)(3) 80000 ADIPOSITY AND TIME RESTRICTED FEEDING IN ADPKD UNIVERSITY OF KANSAS MEDICAL SCHOOL 3901 RAINBOW BLVD 6001 WHE KANSAS CITY KS 66160 481124839 501(C)(3) 240000 PRE-CLINICAL EVALUATION OF CASPASE 1 AS A THERAPEUTIC TARGET IN ADPKDRESCUING POLYCYSTIN-1 G-PROTEIN FUNCTIONUSE OF EXOSOMAL POLYCYSTIN-1 (PC1) LEVEL TO DIAGNOSE AND MONITOR ADPKD UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 212036428 526002033 GOV 140000 POLYCYSTIN-1 CLEAVAGE PRODUCT P100: DISTINCTIVE TOPOLOGY, SPECIFIC PROPERTIES, AND POLYCYSTIN-2-ASSOCIATED CHANNEL ACTIVITYRELIEVING THE STRESS OF PKD: A NEW ROLE OF PKHD1 IN DETOXIFICATION MEDIATED VIA DIFFERENTIAL CLEAVAGE OF THE INTRACELLULAR DOMAIN MAYO CLINIC PO BOX 860334 MINNEAPOLIS MN 55486 416011702 501(C)(3) 226000 THE EFFECT OF DIETARY METHIONINE RESTRICTION ON PATHOGENESIS OF ADPKD AND THERAPEUTIC IMPLICATION OF FGF21 ANALOGUESROLE OF NOX4, MITOCHONDRIA AND RELATED BIOMARKERS IN ADPKD YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 80000 CONTROLLING THE VIABILITY OF PKD MUTANT CELLS VIA INACTIVATION OF XBP1 AS A NOVEL STRATEGY TO TREAT EMORY UNIVERSITY 1670 CLAIRMONT RD 151F DECATUR GA 30033 580566256 501(C)(3) 80000 MACHINE LEARNING FOR PREDICTING EGFR DECLINE IN THE CRISP COHORT OF ADPKD PATIENTS UNIVERSITY OF ALABAMA AT BIRMINGHAM 1720 2ND AVE SOUTH LHBR 621 BIRMINGHAM AL 35294 636005396 501(C)(3) 209964 DEVELOPING EARLY PROGNOSIS IMAGING BIOMARKERS OF ADPKD BASED ON DYNAMIC CHANGES IN CYST GROWN RATESKIDNEY SPECIFIC DRUG DELIVERY USING NANOPARTICLES IN PKD1 MICESALARY SUPPORT BRIGHAM AND WOMEN'S HOSPITAL 77 AVENUE LOUIS PASTEUR 4 BLACKFAN CIRCLE BOSTON MA 02115 416011702 501(C)(3) 80000 ELUCIDATING THE CYSTOGENIC PROTEOME IN POLYCYSTIC KIDNEY DISEASE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 512 RATION PASS IRVING TX 75063 756002868 501(C)(3) 120000 INVESTIGATING THE M6A RNA METHYLATION PATHWAY AS A THERAPEUTIC OPTION FOR ADPKD TREATMENTROLE OF TULP3-MEDIATED CILIARY PROTEIN TRAFFICKING IN KIDNEY CYSTOGENESIS CRITICAL PATH INSTITUTE 1730 EAST RIVER ROAD NO 200 TUCSON AZ 85718 201991334 501(C)(3) 100000 POLYCYSTIC KIDNEY DISEASE OUTCOMES CONSORTIUM 10 0 KAPLAN PRIZES 1 50000 CASH VALUE PART I, LINE 2: ALL GRANTEES ARE REQUIRED TO SUBMIT AN ANNUAL RESEARCH PROGRESS REPORT AND AN ANNUAL INSTITUTIONAL FINANCIAL STATUS REPORT. MOST GRANTEES ARE ALSO REQUIRED TO SUBMIT INTERIM QUARTERLY PROGRESS REPORTS. X X X X 0 0 0 0 0 0 0 0 0 BETTS ANDREW PRESIDENT AND CEO 233310 0 35112 0 0 0 25500 0 28957 0 322879 0 0 0 HANOVA AMANDA CHIEF OPERATING OFFICER 135740 0 20810 0 0 0 14872 0 21710 0 193132 0 0 0 SULLENS STEPHANIE CHIEF ADVANCEMENT OFFICER 148403 0 5000 0 0 0 14573 0 9276 0 177252 0 0 0 BARON DAVID CHIEF RESEARCH OFFICER 148036 0 0 0 0 0 14063 0 10304 0 172403 0 0 0 X 17 9980591 FAIR VALUE X CHAPTER EVENT ITEMS 298 156300 FAIR VALUE X BOARD TRAVEL EXPENSES 52 33873 COST 0 0 1 1 PART I, COLUMN (B): NUMBER OF CONTRIBUTIONS PART I, LINE 32B: ORGANIZATION UTILIZES ONGOING BANKING RELATIONSHIPS TO MARKET DONATED SECURITIES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. PRIOR TO FILING THE FORM 990 FOR PKD FOUNDATION, A DRAFT COPY WILL BE PROVIDED TO THE BOARD OF TRUSTEES FOR REVIEW AND COMMENT. ANY COMMENTS WILL BE ACCUMULATED BY MANAGEMENT AND ADDRESSED ACCORDINGLY PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C MEMBERS OF THE BOARD OF TRUSTEES OF PKD FOUNDATION ARE REQUIRED TO SIGN AN ANNUAL STATEMENT DISCLOSING ANY CONFLICTS OF INTEREST. THE GOVERNANCE COMMITTEE REVIEWS THE STATEMENTS AND ENSURES THAT BOARD MEMBERS ARE PROHIBITED FROM PARTICIPATING IN DISCUSSIONS OR DECISIONS RELATED TO TRANSACTIONS THAT INVOLVE ACTUAL CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 ANNUALLY, THE CHAIR OF THE BOARD OF TRUSTEES WORKS WITH THE CEO TO DEVELOP THE CEO'S GOALS FOR THE NEW FISCAL YEAR. AT THE END OF THE EACH FISCAL YEAR, THE HR COMMITTEE EVALUATES THE CEO AGAINST THESE GOALS AND DETERMINES MERIT AND BONUS LEVELS BASED ON THEIR REVIEW. ANNUALLY, THE HR COMMITTEE REVIEWS A NATIONAL NONPROFIT COMPENSATION REPORT FOR COMPARABILITY DATA FOR THE CEO SALARY. AFTER A FULL REVIEW OF PERFORMANCE AND COMPARABILITY DATA, THE HR COMMITTEE VOTES TO APPROVE ANY SALARY INCREASE AND BONUS AND INFORMS THE FULL BOARD OF TRUSTEES WITH THEIR DECISION. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON THEIR OWN WEBSITE AND UPON REQUEST. FORM 990, PART VII, SECTION A, LINE 1: PKD FOUNDATION CONTRACTS WITH ADP TOTALSOURCE TO PROVIDE CERTAIN EMPLOYEE BENEFITS AND PAYROLL SERVICES. EMPLOYEES ARE CONSIDERED TO BE JOINTLY EMPLOYED BY BOTH PKD FOUNDATION AND ADP TOTALSOURCE. IN ORDER TO COMPLY WITH TRANSPARENCY DIRECTIVES AS A PART OF THE FORM 990, THE FOUNDATION HAS DECIDED TO REPORT COMPENSATION IN PART VII TO INCLUDE AMOUNTS PAID AND REPORTED ON W-2'S BY ADP TOTALSOURCE. FORM 990, PART XI, LINE 9: RETURN OF PRIOR YEAR GRANT 9,533. FORM 990, PART XII, LINE 2 C EXPLANATION: NO CHANGE FROM THE PRIOR YEAR.